Trial Profile
Discontinuation of infliximab therapy after acquisition of low disease activity by infliximab in rheumatoid arthritis study: RRR (remission induction by remicade) study.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 24 Dec 2013
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms RRR-study
- 24 Dec 2011 Planned end date (Dec 2010) added as reported by University Hospital Medical Information Network - Japan.
- 29 Jun 2009 New trial record